News | Stents Drug Eluting | January 10, 2017

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Elastomer-coated DES shows identical target lesion failure, low definite/probable stent thrombosis rate compared to Resolute Integrity stent

Medinol, BIONICS study, 12-month results, TCT 2016, drug-eluting stent, EluNIR

January 10, 2017 — Medinol announced in December positive twelve-month clinical results from the BIONICS study. The study was conducted to evaluate EluNIR, Medinol's novel coronary stent system and the first ever elastomer-coated drug eluting stent (eDES), according to the company.

This global pivotal study enrolled 1,919 patients from 76 sites in eight countries. The BIONICS results were highlighted in the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium, Oct. 29-Nov. 2 in Washington, D.C. The study data will be submitted to the U.S. Food and Drug Administration (FDA) to support the U.S. regulatory approval of EluNIR for the treatment of patients with narrowing or blockage of their coronary arteries.

The BIONICS study — a global, prospective, randomized, multicenter, non-inferiority clinical trial — was designed to include a "more comers" population, i.e. one that closely represents the real-world patient population. The EluNIR Stent (study name BioNIR) was compared to the Resolute Integrity Stent (1:1 randomization). Key results from the study include:

  • For its primary endpoint of target lesion failure (TLF), EluNIR demonstrated a rate of 5.4 percent at 12 months compared to an identical rate of 5.4 percent for Resolute (p=0.0013 for non-inferiority). TLF was defined as the composite of cardiac death, target vessel MI and clinically driven TLR; and
  • Good safety profile, with a low definite/probable stent thrombosis rate of 0.4 percent for EluNIR, compared to 0.8 percent for Resolute (p=NS), with no events beyond 30 days for EluNIR.    

"The BIONICS data validated that the EluNIR stent performed very well in a more broad, less selected 'more comers' population than has previously been studied for most other DES," said David Kandzari, M.D., F.A.C.C., director of interventional cardiology at Piedmont Heart Institute, Atlanta, and principal investigator for the BIONICS trial. "These results establish the excellent clinical performance of this stent, and we look forward to seeing the angiographic data over the next few months to further support its efficacy."

In addition to the BIONICS study, new twelve-month data from NIREUS, the European pivotal trial for EluNIR, were presented at TCT. The NIREUS study — a prospective, multi-center, randomized, non-inferiority pivotal study comparing EluNIR to the Resolute Integrity Stent — met its non-inferiority primary endpoint of angiographic in-stent late loss at six months. These data were presented at EuroPCR in May 2016. The recent twelve-month clinical data, presented TLF of 3.4 percent for EluNIR and 5.9 percent for Resolute (p=NS).These outcomes were consistent with the positive results of BIONICS.

For more information:

Related Content

transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access| February 22, 2017
If hospitals can perform more transradial, same-day percutaneous coronary intervention (PCI), hospitals across the U.S...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Sponsored Content | Videos | 3-D Printing| February 09, 2017
When a pediatric patient at Children’s Hospital Los Angeles needed a custom-build stent to repair his pulmonary arter
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Tendyne Mitral valve

The Tendyne mitral valve being implanted. 

News | Heart Valve Technology| January 16, 2017
January 16, 2017 – In 2015, researchers and physicians at the Minneapolis Heart Institute Foundation (MHIF) were the
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Sponsored Content | Videos | Cardiovascular Ultrasound| January 13, 2017
Detailed imaging is needed to support complex interventions for the assessment and procedure guidance.
Overlay Init